We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

197 hedge funds and large institutions have $477M invested in SANGAMO THERAPEUTICS INC in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 46 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 46

39% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 23

29% more capital invested

Capital invested by funds: $370M → $477M (+$107M)

24% more call options, than puts

Call options by funds: $2.45M | Put options by funds: $1.97M

5% more funds holding

Funds holding: 188197 (+9)

1.07% more ownership

Funds ownership: 61.14%62.21% (+1.1%)

Holders
197
Holders Change
+9
Holders Change %
+4.79%
% of All Funds
3.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
32
Increased
68
Reduced
46
Closed
23
Calls
$2.45M
Puts
$1.97M
Net Calls
+$478K
Net Calls Change
-$539K
Name Holding Trade Value Shares
Change
Change in
Stake
Nordea Investment Management
26
Nordea Investment Management
Sweden
$3.43M +$5.14K +1,000 +0.1%
LOAMS
27
Lombard Odier Asset Management (Switzerland)
Switzerland
$3.34M -$496K -96,469 -12%
Mirae Asset Global Investments
28
Mirae Asset Global Investments
South Korea
$3.12M +$422K +82,067 +15%
Millennium Management
29
Millennium Management
New York
$3.06M -$2.98M -581,055 -48%
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.96M +$1.12M +218,812 +57%
LFCM
31
Long Focus Capital Management
Puerto Rico
$2.6M
Bank of New York Mellon
32
Bank of New York Mellon
New York
$2.52M +$265K +51,585 +11%
Wells Fargo
33
Wells Fargo
California
$2.19M -$151K -29,482 -6%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$2.15M +$662K +128,898 +42%
Citadel Advisors
35
Citadel Advisors
Florida
$2.1M -$1.01M -195,848 -31%
Massachusetts Financial Services
36
Massachusetts Financial Services
Massachusetts
$2.05M +$2.15M +418,562 New
State of New Jersey Common Pension Fund D
37
State of New Jersey Common Pension Fund D
New Jersey
$2.05M +$2.15M +418,017 New
Macquarie Group
38
Macquarie Group
Australia
$1.97M -$9.63K -1,875 -0.5%
Citigroup
39
Citigroup
New York
$1.95M +$260K +50,655 +15%
Barclays
40
Barclays
United Kingdom
$1.79M +$1.35M +262,234 +254%
ECM
41
ExodusPoint Capital Management
New York
$1.73M +$202K +39,288 +13%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$1.71M +$849K +165,234 +90%
William Blair & Company
43
William Blair & Company
Illinois
$1.69M
Federated Hermes
44
Federated Hermes
Pennsylvania
$1.64M -$2.03M -395,565 -54%
Swiss National Bank
45
Swiss National Bank
Switzerland
$1.44M
Axa
46
Axa
France
$1.43M +$1.5M +291,800 New
Ohio Public Employees Retirement System (OPERS)
47
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.4M
Group One Trading
48
Group One Trading
Illinois
$1.36M +$140K +27,338 +11%
CSS
49
Cubist Systematic Strategies
Connecticut
$1.07M -$1.07M -208,845 -49%
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$962K +$842K +164,006 +507%

SGMO Hedge Fund Activity: Q3 2022 in Review

197 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2022, worth a combined $477M — up 29% from $370M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SGMO positions and 23 closed out — a net gain of 9 holders — while 68 added to existing stakes and 46 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $12.1M. The largest seller was Casdin Capital, exiting entirely with an estimated $4.14M sold.

  • 197 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2022, up from 188 in Q2 2022.
  • Funds reported $477M of SANGAMO THERAPEUTICS INC stock for Q3 2022, up 29% quarter-over-quarter.
  • 32 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2022 and 23 closed out, a net change of +9 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q3 2022 was Avidity Partners Management, an estimated $12.1M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q3 2022 was Casdin Capital, an estimated $4.14M sold.

Based on aggregated 13F filings for Q3 2022.